Oxford Biodynamics Plc (Oxford Biodynamics) is a developer of biomarker discovery platform. The company concentrates on research in detection, monitoring and prognosis of major diseases associated with aberrant gene expression such as oncology, metabolic, inflammatory, cardiovascular and neurodegenerative conditions. Its biomarker discovery platform is used for the detection of aberrant gene expressions. The company's products are used in the areas of breast cancer diagnostics, hepatocellular carcinoma diagnostics, nasopharyngeal carcinoma diagnostics, prostate cancer progression, melanoma diagnostics and age-related disease diagnostics. Oxford Biodynamics is headquartered in Oxford, Oxfordshire, the UK.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Oxford Biodynamics Plc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
Oxford Biodynamics Plc Company Overview
Oxford Biodynamics Plc Company Snapshot
Oxford Biodynamics Plc Pipeline Products and Ongoing Clinical Trials Overview
EpiSwitch Prostate Cancer Prognostic Assay Product Overview
EpiSwitch Relapsing Remitting Multiple Sclerosis Test
EpiSwitch Relapsing Remitting Multiple Sclerosis Test Product Overview
EpiSwitch Rheumatoid Arthritis Predictive Biomarker Test
EpiSwitch Rheumatoid Arthritis Predictive Biomarker Test Product Overview
EpiSwitch Systemic Lupus Erythematosus Prognostic Test
EpiSwitch Systemic Lupus Erythematosus Prognostic Test Product Overview
EpiSwitch T1DM Diagnostic Test
EpiSwitch T1DM Diagnostic Test Product Overview
EpiSwitch T1DM Prognostic Test
EpiSwitch T1DM Prognostic Test Product Overview
EpiSwitch T2DM Prognostic Test
EpiSwitch T2DM Prognostic Test Product Overview
EpiSwitch Test - Huntington's Disease
EpiSwitch Test - Huntington's Disease Product Overview
EpiSwitch Thyroid Cancer Diagnostic Test
EpiSwitch Thyroid Cancer Diagnostic Test Product Overview
EpiSwitch Ulcerative Colitis Test
EpiSwitch Ulcerative Colitis Test Product Overview
Oxford Biodynamics Plc - Key Competitors
Oxford Biodynamics Plc - Key Employees
Oxford Biodynamics Plc - Locations And Subsidiaries
Head Office
Recent Developments
Oxford Biodynamics Plc, Recent Developments
Apr 03, 2024: Oxford Biodynamics opens clinical testing facility in the UK to perform EpiSwitch Prostate Screening (PSE) blood test
Nov 08, 2023: Oxford Biodynamics Strengthens Commercial Leadership With New SVP of Business and Corporate Development
Oct 03, 2023: Oxford Biodynamics Receives Reimbursement Code for Episwitch Prostate Screening (PSE) Test
Sep 26, 2023: Oxford Biodynamics Announces US Launch of its 94% Accurate EpiSwitch Prostate Screening Blood Test to Men With Prostate Cancer Risk
May 16, 2023: Oxford BioDynamics notice of interim results and investor webinar
May 15, 2023: Oxford BioDynamics : Peer-reviewed study results confirm and expand validation of Oxford BioDynamics' EpiSwitch CiRT blood test for checkpoint inhibitor immunotherapies
May 02, 2023: Oxford Biodynamics Granted US Foundation of NIH Pact Award for Prognosis of Cancer Patients with IO-Triggered Hyper-Progressive Disease
Apr 05, 2023: Business update - plan to launch Prostate Screening EpiSwitch test by end of 2023; sales progress for flagship EpiSwitch CiRT
Feb 08, 2023: The new prostate cancer blood test with 94 per cent accuracy
Feb 06, 2023: Oxford BioDynamics’ prostate screening EpiSwitch blood test significantly enhances overall detection accuracy for at risk men